羟氯喹治疗类风湿关节炎的临床研究现状 : = Research status of hydroxychloroquine in the treatment of rheumatoid arthritis
羟氯喹(HCQ)是一种缓解类风湿关节炎(RA)病情的药物,在RA治疗中占据重要地位,已被国内外多个RA诊疗指南所推荐。近年来,许多基础和临床研究显示,HCQ不仅在控制RA疾病具有良好的有效性与安全性,还能有效改善RA患者的多种合并症,如高脂血症和心血管疾病等。本文旨在对HCQ在RA治疗中的有效性与安全性方面的研究现状进行全面地综述。.
Hydroxychloroquine,one of disease-modifying anti-rheumatic drugs,plays an important role in the treatment of rheumatoid arthritis(RA) and has been recommended by lots of clinical recommendations or guidelines.In recent years,a number of experimental and clinical observations have outlined that hydroxychloroquine was not only effective and safe in controlling RA disease activity itself,but provided several additional clinical benefits as well,such as improving metabolic status,lowing cardiovascular risk.This review gives a comprehensive overview of the efficacy and safety of hydroxychloroquine in the management of RA..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019-12-17 2019 |
|---|---|
| Erschienen: |
2019-12-17 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2019 |
|---|---|
| Enthalten in: |
Zhong guo lin chuang yao li xue za zhi - (2019), 23 vom: 17. Dez., Seite 3134-3137 Original Letters: Enthalten in 中国临床药理学杂志 (DE-600)2991262-3 (DE-600)2991262-3 北京市 |
| Reihe: |
China Academic Journals (CAJ), E, 医药卫生科技 = Medicine & Public Health |
|---|
| Sprache: |
Chinesisch |
|---|
| Weiterer Titel: |
Research status of hydroxychloroquine in the treatment of rheumatoid arthritis |
|---|
| Beteiligte Personen: |
|---|
| Links: |
oversea.cnki.net [lizenzpflichtig] |
|---|
| Themen: |
临床获益 |
|---|
| Anmerkungen: |
Author info:XIE Wen-hui;ZHANG Zhuo-li;Department of Rheumatology and Clinical Immunology,Peking University First Hospital |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
CAJ646088742 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CAJ646088742 | ||
| 003 | DE-627 | ||
| 005 | 20230121124215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230104s2019 cc |||||o 00| ||chi c | ||
| 035 | |a (DE-627)CAJ646088742 | ||
| 035 | |a (SBB-XA)CAJ_GLYZ201923053 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 044 | |c XB-CN | ||
| 084 | |a ASIEN |q DE-1a |2 fid | ||
| 084 | |a R593.22 |2 clc | ||
| 100 | 0 | |a 谢文慧 |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 羟氯喹治疗类风湿关节炎的临床研究现状 |b = Research status of hydroxychloroquine in the treatment of rheumatoid arthritis |
| 246 | 3 | 1 | |a Research status of hydroxychloroquine in the treatment of rheumatoid arthritis |
| 264 | 1 | |c 2019-12-17 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a China Academic Journals (CAJ) |a E |a 医药卫生科技 = Medicine & Public Health | |
| 500 | |a Author info:XIE Wen-hui;ZHANG Zhuo-li;Department of Rheumatology and Clinical Immunology,Peking University First Hospital | ||
| 520 | |a 羟氯喹(HCQ)是一种缓解类风湿关节炎(RA)病情的药物,在RA治疗中占据重要地位,已被国内外多个RA诊疗指南所推荐。近年来,许多基础和临床研究显示,HCQ不仅在控制RA疾病具有良好的有效性与安全性,还能有效改善RA患者的多种合并症,如高脂血症和心血管疾病等。本文旨在对HCQ在RA治疗中的有效性与安全性方面的研究现状进行全面地综述。 | ||
| 520 | |a Hydroxychloroquine,one of disease-modifying anti-rheumatic drugs,plays an important role in the treatment of rheumatoid arthritis(RA) and has been recommended by lots of clinical recommendations or guidelines.In recent years,a number of experimental and clinical observations have outlined that hydroxychloroquine was not only effective and safe in controlling RA disease activity itself,but provided several additional clinical benefits as well,such as improving metabolic status,lowing cardiovascular risk.This review gives a comprehensive overview of the efficacy and safety of hydroxychloroquine in the management of RA. | ||
| 610 | 2 | 4 | |a 北京大学第一医院风湿免疫科 |
| 650 | 4 | |a 全身性疾病、地方病学 | |
| 650 | 4 | |a 内科学 | |
| 650 | 4 | |a 医药、卫生 | |
| 650 | 4 | |a Endocrine and Systemic Disease | |
| 650 | 4 | |a 医药卫生科技 | |
| 650 | 4 | |a Medicine & Public Health | |
| 650 | 4 | |a 羟氯喹 | |
| 650 | 4 | |a 类风湿关节炎 | |
| 650 | 4 | |a 疗效 | |
| 650 | 4 | |a 安全性 | |
| 650 | 4 | |a 临床获益 | |
| 650 | 4 | |a hydroxychloroquine | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a clinical benefit | |
| 700 | 0 | |a 张卓莉 |4 oth | |
| 773 | 0 | 8 | |6 880-01 |i Enthalten in |t Zhong guo lin chuang yao li xue za zhi |d Bei jing shi, 1985 |g (2019), 23 vom: 17. Dez., Seite 3134-3137 |h Online-Ressource |w (DE-627)CAJ142435430 |w (DE-600)2991262-3 |7 nnns |
| 773 | 1 | 8 | |g year:2019 |g number:23 |g day:17 |g month:12 |g pages:3134-3137 |
| 856 | 4 | 0 | |u http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201923053 |x Verlag |y CrossAsia Link |z Deutschlandweit zugänglich |
| 856 | 4 | 0 | |u https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201923053 |x Verlag |z lizenzpflichtig |
| 880 | 0 | 8 | |6 773-01/Hans |i Enthalten in |t 中国临床药理学杂志 |d 北京市 |h Online-Ressource |w (DE-627)CAJ142435430 |w (DE-600)2991262-3 |7 nnns |
| 912 | |a ZDB-1-CAJ | ||
| 912 | |a GBV_NL_CAJ | ||
| 912 | |a FID-ASIEN | ||
| 912 | |a SSG-OLC-OA3.1 | ||
| 912 | |a SSG-OLC-CAJ | ||
| 936 | u | w | |j 2019 |e 23 |b 17 |c 12 |h 3134-3137 |
| 951 | |a AR | ||
| 952 | |j 2019 |e 23 |b 17 |c 12 |h 3134-3137 | ||
| 980 | |2 11 |1 01 |x 0001 |b 665593473 |c 00 |f 5:FIDXASIA |d --%%-- |e --%%-- |j --%%-- |y k |z 04-01-23 | ||
| 981 | |2 11 |1 01 |x 0001 |r http://erf.sbb.spk-berlin.de/han/caj/oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ201923053 | ||